心包切开术后综合征诊治进展

Advancements in diagnosis and treatment of postpericardiotomy syndrome

心包切开术后综合征(postpericardiotomy syndrome,PPS)是一种炎性胸膜心包综合征,发病因素包括自身免疫、特殊病毒、潜伏病毒感染再发作等。PPS具有自限性,但可以长期迁延。发生PPS的患者,住院时间显著延长,再入院率升高,有创介入性操作增加。PPS的治疗主要是基于经验应用抗炎药物。临床研究显示单药应用秋水仙碱具有预防术后PPS的作用,但并不能降低术后心房颤动、心包积液以及胸腔积液的发生率。本文主要分析PPS的发病率、高危因素、临床特征、诊治标准、预防措施以及预后。

The postpericardiotomy syndrome（PPS） is an inflammation of the pericardium or pleura following a variety of pericardial injuries. The potential pathogenic factors of the PPS are autoimmune, special virus and latent virus infection. PPS is self-limited, but may lead to prolonged hospital stay, readmissions, and need for invasive interventions.The therapy for PSS is mainly empiric anti-inflammatory therapy. The perioperative use of colchicine could reduce the incidence of PPS but is not effective for postoperative atrial fibrillation or postoperative pericardial/pleural effusion. This article mainly analyzes the incidence, risk factors, clinical features, diagnosis and treatment standards, preventive measures and prognosis of PPS.